Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Conditions:   COVID-19;   COVID-19 Acute Respiratory Distress Syndrome Interventions:   Drug: TTI-0102;   Drug: Placebo Sponsor:   Thiogenesis Therapeutics, Inc. Not yet recruiting

Source: ClinicalTrials.gov - January 28, 2022 Category: Research Source Type: clinical trials